Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. Less than 5 mm Endometrio despite 10 days with standard doses of estrogen therapy (6mg / 24h)
Conditions
Interventions
Product Name: PRP (Obtenido por PRGF-Endoret)
Pharmaceutical Form: Blood fraction modifier
INN or Proposed INN: Platelet Rich Plasma
Other descriptive name: AUTOLOGOUS PLASMA
Concentration unit: ml m
Sponsors
IVI BILBAO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. - Less than 5mm despite 10 days with standard doses of estrogen therapy (6mg / 24h) Endometrio Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 32 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: - History of pelvic inflammatory disease - Risk of infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: knowing the clinical value of using the PRGF-Endoret therapy and endometrial level applications to improve endometrial thickness endometrial preparations for embryo transfer.;Secondary Objective: 1. To evaluate the growth of endometrial thickness from the end of usual procedure stimulation until the end of use of the platelet plasma. 2. Analyze the impact of using platelet plasma on rates of implantation and pregnancy.;Primary end point(s): It is to find at least one difference 2mm increased endometrial wall;Timepoint(s) of evaluation of this end point: - Recruitment Period: June to October 2016 - Estimated to last patient treatment Date: January 2017 - End of the study Date: May 2017 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): ASSESSMENT OF THE RATE OF IMPLEMENTATION Apply a bilateral Student t test comparison of the average rate of implementation in IVI over the past 4 years. ASSESSMENT OF PREGNANCY RATE Similarly, we apply a test of Fisher on a 2x2 design based on the results of gestation. It will be used as contrast group data IVI Bilbao in the last 4 years.;Timepoint(s) of evaluation of this end point: - Recruitment Period: June to October 2016 - Estimated to last patient treatment Date: January 2017 - End of the study Date: May 2017 | — |
Countries
Spain
Contacts
Public ContactFERNANDO QUINTANA
IVI BILBAO
Outcome results
None listed